O'Sullivan, J., Hamblin, A., Yap, C., Fox, S., Boucher, R., A, P., . . . Mead, A. (2019). The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. American Society of Hematology.
Chicago Style (17th ed.) CitationO'Sullivan, JM, et al. The Poor Outcome in High Molecular Risk, Hydroxycarbamide-resistant/intolerant ET Is Not Ameliorated by Ruxolitinib. American Society of Hematology, 2019.
MLA (9th ed.) CitationO'Sullivan, JM, et al. The Poor Outcome in High Molecular Risk, Hydroxycarbamide-resistant/intolerant ET Is Not Ameliorated by Ruxolitinib. American Society of Hematology, 2019.
Warning: These citations may not always be 100% accurate.